

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## MULTICENTRIC, OBSERVATIONAL, LONGITUDINAL STUDY FOR THE EVALUATION OF NUTRITIONAL MANAGEMENT IMPLICATIONS IN NEWLY DIAGNOSED ITALIAN CANCER PATIENTS: THE ITALIAN REGISTRY OF MALNUTRITION IN ONCOLOGY (IRMO)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-071858
Article Type:	Protocol
Date Submitted by the Author:	13-Jan-2023
Complete List of Authors:	<p>Bosetti, Cristina; Istituto di Ricerche Farmacologiche Mario Negri, Department of Oncology</p> <p>Casirati, Amanda; Fondazione IRCCS Policlinico San Matteo, Clinical Nutrition and Dietetics Unit</p> <p>Da Prat, Valentina; Fondazione IRCCS Policlinico San Matteo, Clinical Nutrition and Dietetics Unit</p> <p>Masi, Sara; Fondazione IRCCS Policlinico San Matteo, Clinical Nutrition and Dietetics Unit</p> <p>Crotti, Silvia; Fondazione IRCCS Policlinico San Matteo, Clinical Nutrition and Dietetics Unit</p> <p>Ferrari, Alessandra; Fondazione IRCCS Policlinico San Matteo, Medical Oncology Unit</p> <p>Perrone, Lorenzo; Fondazione IRCCS Policlinico San Matteo, Medical Oncology Unit</p> <p>Serra, Francesco; Fondazione IRCCS Policlinico San Matteo, Medical Oncology Unit</p> <p>Santucci, Claudia; Istituto di Ricerche Farmacologiche Mario Negri, Department of Oncology</p> <p>Cereda, Emanuele; Fondazione IRCCS Policlinico San Matteo, Clinical Nutrition and Dietetics Unit</p> <p>Iannelli, Elisabetta; Italian Federation of Volunteer-based Cancer Organizations</p> <p>De Lorenzo, Francesco; Italian Federation of Volunteer-based Cancer Organizations, Rome, Italy</p> <p>Pedrazzoli, Paolo; Fondazione IRCCS Policlinico San Matteo; University of Pavia, Internal Medicine Department</p> <p>Caccialanza, R; Fondazione IRCCS Policlinico San Matteo, Clinical Nutrition and Dietetics Unit</p> <p>IRMO Collaborators, IRMO Collaborators; Fondazione IRCCS Policlinico San Matteo</p>
Keywords:	Quality of Life, Nutritional support < ONCOLOGY, REGISTRIES

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 **MULTICENTRIC, OBSERVATIONAL, LONGITUDINAL STUDY FOR THE**  
4 **EVALUATION OF NUTRITIONAL MANAGEMENT IMPLICATIONS IN NEWLY**  
5 **DIAGNOSED ITALIAN CANCER PATIENTS: THE ITALIAN REGISTRY OF**  
6 **MALNUTRITION IN ONCOLOGY (IRMO)**  
7  
8  
9  
10  
11  
12  
13

14 Cristina Bosetti<sup>1§</sup>, Amanda Casirati<sup>2</sup>, Valentina Da Prat<sup>2</sup>, Sara Masi<sup>2</sup>, Silvia Crotti<sup>2</sup>,  
15 Alessandra Ferrari<sup>3</sup>, Lorenzo Perrone<sup>3</sup>, Francesco Serra<sup>3</sup>, Claudia Santucci<sup>1</sup>,  
16 Emanuele Cereda<sup>2</sup>, Elisabetta Iannelli<sup>4</sup>, Francesco De Lorenzo<sup>4</sup>, Paolo Pedrazzoli<sup>3,5,§</sup>,  
17 Riccardo Caccialanza<sup>2§</sup>, on behalf of the IRMO collaborators\*  
18  
19  
20  
21  
22  
23  
24  
25

26 <sup>1</sup>Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan,  
27 Italy  
28

29 <sup>2</sup>Clinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy  
30

31 <sup>3</sup>Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy  
32

33 <sup>4</sup>Italian Federation of Volunteer-based Cancer Organizations, Rome, Italy  
34

35 <sup>5</sup>Internal Medicine Department, University of Pavia, Pavia, Italy  
36

37 § Co-senior authors.  
38  
39  
40  
41  
42  
43  
44

45 **Corresponding author:**

46 Dr. Riccardo Caccialanza

47 Clinical Nutrition and Dietetics Unit

48 Fondazione IRCCS Policlinico San Matteo

49 Viale Golgi 19 - 27100 Pavia, Italy

50 Tel.: +39 0382501615; fax: + 39 0382502801. E-mail: [r.caccialanza@smatteo.pv.it](mailto:r.caccialanza@smatteo.pv.it)  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

### Introduction

Malnutrition is a frequent problem in oncology and is associated with reduced response to cancer treatments, increased drug-related toxicity, higher rates of clinical complications, reduced quality of life (QoL), and worse prognosis. Guidelines on clinical nutrition in oncology emphasize the usefulness of early assessment of nutritional status for a prompt identification of malnutrition and the implementation of effective interventions, but no real-world clinical data are available on the adequate management of nutritional support in cancer patients in Italy.

### Methods and Analysis

This is an observational, longitudinal, multicenter registry of patients with a new diagnosis of cancer or metastatic disease, candidates for active treatment. They will be identified in at least 15 Italian oncologic centers, members of the Alliance Against Cancer Working Group “Survivorship Care and Nutritional Support”. At least 1500 cancer patients are expected to be enrolled each year. Detailed clinical and nutritional data will be collected by oncologists and clinical nutritionists during the visits foreseen in the clinical practice, through an *ad hoc* developed digital platform (e-Nutracare®). The effects of malnutrition and nutritional support – at diagnosis and during follow-up – on overall survival and progression-free survival, as well as on patients’ symptoms and QoL, will be investigated.

### Ethics and Dissemination

The study protocol was approved by Ethics Committee of the Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and from the Ethics Committees of all other participating centers. An informed consent will be obtained from each patient enrolled in the study. Study findings will be disseminated through peer-reviewed journals, conferences, and cancer patients or professional associations. The registry will allow a better monitoring of the nutritional status

1  
2  
3 of cancer patients, promoting adequate and sustainable nutritional support, with the ultimate  
4  
5 goal of improving the care and prognosis of these patients.  
6  
7  
8  
9

10 **Keywords:** cancer-related malnutrition, nutritional management, prospective study, quality of  
11  
12 life, real-world data, registry, survival.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

### STRENGTHS AND LIMITATIONS OF THIS STUDY

- The study will allow the implementation of the first Italian, real-world register for detecting and monitoring malnutrition in cancer patients.
- The study will make use of an *ad hoc* developed digital platform for data collection, which could be proposed and extended in the near future to other oncologic centers within the national territory.
- The study will allow a more appropriate evaluation and monitoring of cancer patients' nutritional status, promoting adequate and sustainable nutritional support, with the ultimate goal of improving the quality of care and prognosis.
- Study limitations consist in the observational design, which will not allow to compare the efficacy of personalized nutritional support interventions in specific oncologic diseases.

## INTRODUCTION

Malnutrition is a frequent problem in oncology and is associated with a reduced response to cancer treatment, an increase in treatment-related toxicity, higher occurrence of clinical symptoms and complications, impaired quality of life (QoL), and worse overall prognosis [1-6]. Different causes are linked to this condition, including factors such as cancer site and metastatic localizations, and the deregulation of systemic inflammation pathways [5]. Medical treatments and surgery could also be responsible for nutritional derangements, through the increase of basal caloric requirements and the occurrence of symptoms that negatively impact on food intake and nutrient absorption (e.g., anorexia, mucositis, dysphagia, smell alterations, taste alterations, xerostomia, vomiting, nausea, diarrhea, etc.). Taken together, these factors impair the maintenance of functional body composition [3-5,7].

Sarcopenia (i.e., the loss of skeletal muscle and strength) is the main issue which contributes to functional deterioration in cancer patients [8]. In particular, it has been observed that handgrip strength assessment is a reliable survival predictor associated with body composition variations, being also a good indicator of functional capacities in chronic diseases [9]. In oncology, low handgrip strength levels are associated with fatigue, impaired QoL, treatment-related toxicity, and higher mortality [10,11].

National and international guidelines on clinical nutrition in oncology – including those issued by the Italian Ministry of Health in 2017 [12] – underline the utility of early evaluation of nutritional status in cancer patients and of a prompt and appropriate nutritional support, whenever indicated, in order to prevent or treat malnutrition, improve patients' clinical outcomes and QoL, and increase the efficacy and tolerability of cancer treatments [3-5,12]. Only an early and adequate nutritional support can effectively prevent or treat malnutrition and support cancer patients during their entire illness trajectory.



1  
2  
3 Despite these indications, there are several are critical issues related to the quality of  
4 nutritional care in oncology, and no reliable data are available on the current implementation  
5 of adequate nutritional support in cancer patients in Italy. Nowadays, only real-world data  
6 collected by administrative databases are available in the context of nutrition in oncology, but  
7 these have various inherent weaknesses, which somehow limit the possibility to interpret their  
8 evidence from a clinical point of view [13,14]. Therefore, it is of foremost importance to start  
9 collecting real-world clinical data on malnutrition in oncology, in order to strengthen the  
10 evidence and concretely improve nutritional care practices.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 Based on these premises, the study “Italian Registry of Malnutrition in Oncology (IRMO)”  
22 has been elaborated in collaboration with the oncologic centers that joined the Working Group  
23 (WG) “Survivorship Care and Nutritional Support” of Alliance Against Cancer (Alleanza  
24 Contro il Cancro, ACC). This study aims to set up a digital register of newly diagnosed cancer  
25 patients, in order to monitor their nutritional status and explore the implications of their  
26 nutritional support. This will represent the first national, real-world register for detecting and  
27 monitoring malnutrition in cancer patients and will allow the creation of a multicentric,  
28 longitudinal cohort of oncologic patients to be used for specific analyses.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

## 42 **METHODS AND ANALYSIS**

### 43 *Study design*

44  
45 This is a multicentric, longitudinal, observational registry of newly diagnosed cancer patients,  
46 candidate for active treatment. Detailed clinical and nutritional data will be collected by  
47 oncologists and clinical nutritionists during the visits foreseen in the clinical practice, through  
48 the *ad hoc* developed digital platform, e-Nutrare®. The initial duration of the study is of  
49 three years. Patients’ enrolment and follow-up will last for all the duration of the study.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 However, for the primary and secondary endpoints of the study only patients enrolled during  
4  
5 the first year and followed-up for another year will be analyzed.  
6  
7  
8  
9

### 10 *Study subjects*

11  
12 Individuals enrolled in the study will be all consecutive newly diagnosed or treated cancer  
13  
14 patients, candidate for active treatment identified in a least 15 Italian IRCCS members of the  
15  
16 ACC WG “Survivorship Care and Nutritional Support” (**Figure 1**). They should be aged 18  
17  
18 years or more, had a new diagnosis of selected cancer sites (i.e., head and neck,  
19  
20 esophagus/stomach, colorectal, hepato-biliary, pancreatic, lung, prostate, other urogenital,  
21  
22 breast, gynecological, soft tissue sarcomas, and melanoma), or a new diagnosis of metastatic  
23  
24 disease, be eligible for active treatment, and provide informed consent to participate in the  
25  
26 registry. Individuals with impossibility to undertake the expected measurements or to  
27  
28 guarantee the attendance of the follow-up visits will be excluded.  
29  
30  
31  
32  
33  
34

### 35 *The digital platform e-Nutracare®*

36  
37 The registry data will be collected through e-Nutracare® (OPT S.r.l., Milan, Italy), a digital,  
38  
39 web-based platform specifically designed to provide the participating centers with the  
40  
41 necessary resources for data collection. The platform is accessible via an internet browser,  
42  
43 without the installation of application modules. It will enable both real-time data collection  
44  
45 during routine clinical practice visits and transmission of information to various health  
46  
47 professionals who participate in the study, thus facilitating their work, involvement, and  
48  
49 collaboration.  
50  
51  
52

53  
54 Data will be entered in single data-entry. In the electronic database, patients will be identified  
55  
56 through a unique identification code to preserve their anonymity. Separately, a list of codes  
57  
58 and corresponding identification of patients’ data will be kept. Data completeness and  
59  
60

1  
2  
3 plausibility will be remotely assessed. Once the corrections have been completed (“cleaned”  
4 database), the database will be frozen (“closed” database). Access to the application by users  
5  
6 will take place only in HTTPS, therefore the information will be always transmitted through  
7  
8 an encrypted channel. Data correction after the database closure will have to be jointly agreed  
9  
10 by the Research Manager, the Statistician and the Data Manager and appropriately  
11  
12 documented. The number of screened patients, of eligible patients and the reason for non-  
13  
14 enrollment will also be documented.  
15  
16  
17  
18  
19  
20

### 21 *Assessments*

22  
23 Medical oncologists will collect baseline data at the first patient’s visit and will carry out  
24  
25 subsequent assessments during the oncologic scheduled visits, according to treatment and  
26  
27 follow-up protocols envisaged for these patients in the clinical practice. All collected  
28  
29 variables, resumed in **Table 1**, will include:  
30  
31

- 32 i) demographic, anamnestic, and clinical data (such as age, sex, cancer type, tumor stage and  
33 comorbidities);
  - 34 ii) oncologic treatments and related severe (grade  $\geq 3$ ) adverse effects or complications,  
35 according to Common Terminology Criteria for Adverse Events (CTCAE v5.0) [15];
  - 36 iii) anthropometric measurements (actual body weight, height, body mass index, weight and  
37 weight trend in the previous six months);
  - 38 iv) performance status according to the Eastern Cooperative Oncology Group (ECOG)  
39 Performance Status Scale [16];
  - 40 v) patients’ symptoms by the Edmonton Symptom Assessment Scale [17];
  - 41 vi) QoL assessed using the Short Form 12 questionnaire [18];
  - 42 vii) disease outcomes (as progression or death).
- 43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Using anthropometric and nutritional data collected, the Nutritional Risk Screening 2002 (NRS 2002) will be calculated [5,19]. The NRS 2002 is a tool developed by the European Society of Clinical Nutrition and Metabolism, which is currently used to identify patients at risk of surgical complications and mortality and has been recently proposed as a useful tool for indicating the need of an early nutritional intervention in cancer patients [20-22].

Patients at risk of malnutrition (NRS 2002 score  $\geq 3$ ) will be referred for a nutritional examination. Clinical nutritionists will collect the following information:

- i) detailed patient' nutritional requirements, nutritional support provided and adherence to the Mediterranean Diet using a validated food frequency questionnaire [23];
- ii) body composition parameters obtained throughout scans of computed tomography (CT) at third level of lumbar (L3) or cervical (C3) vertebra as skeletal muscle (SM) and bioelectrical impedance vector analysis (BIVA), as phase angle (PhA), standardized phase angle (SPhA) and fat-free mass (FFM). The measurements will be based on the availability of instrumentation at the different participating centers.

Every effort will be made to ensure the accuracy of patients monitoring and to avoid patients' loss at follow-up.

**Table 1.** Collected variables.

Age, sex, cancer diagnosis, tumor stage, comorbidities.
Actual body weight, height, BMI, weight loss in the previous 6 months, NRS 2002 score.
Body composition parameters using BIVA (PhA, SPhA, FFM) and CT (SM).
Oncologic treatment, severe adverse effects (grade $\geq 3$ CTCAE).
Performance status (ECOG Scale).
Symptoms (ESAS Scale), QoL (Short Form 12).
Disease outcome (progression or death).

Abbreviations: BIVA, bioelectrical impedance vector analysis; BMI, body mass index; CT, computed tomography; CTCAE, Common Terminology Criteria for Adverse Events; ECOG, Eastern Cooperative Oncology Group; ESAS, Edmonton Symptom Assessment Scale; FFM, fat free mass; NRS 2002, Nutritional Risk Screening 2002; PhA, phase angle; QoL, quality of life; SM, skeletal muscle; SPhA, standardized phase angle.

### *Study endpoints*

Study endpoints are described in **Table 2**. The primary endpoint will be 1-year Overall Survival (OS) and Progression Free Survival (PFS) according to patients' risk of malnutrition (defined as NRS 2002 score  $\geq 3$ ) upon diagnosis.

Secondary endpoints will be 1-year OS and PFS according to malnutrition risk upon diagnosis in relation to cancer type, disease stage, nutritional risk changes and body weight changes during follow-up (at 3, 6, 9, 12 months).

As explorative endpoints, we will investigate 1-year OS and PFS according to the type and timing of nutritional support provided and body composition as well as the rate of severe toxicities (grade III/IV) and discontinuation or delay of treatment according to NRS 2002 score and body composition. Furthermore, we will explore the correlations between NRS 2002 score, body composition parameters, type and timing of nutritional support, QoL, symptoms, and toxicities during follow-up.

**Table 2.** Study endpoints.

<b>Primary endpoint</b>
<ul style="list-style-type: none"> <li>To assess 1-year OS and PFS according to the NRS 2002 cut-off score <math>\geq 3</math> upon diagnosis.</li> </ul>
<b>Secondary endpoints</b>
<ul style="list-style-type: none"> <li>To assess 1-year OS and PFS according to the NRS 2002 cut-off score <math>\geq 3</math> upon diagnosis of metastatic disease.</li> <li>To assess 1-year OS and PFS according to the NRS 2002 cut-off score <math>\geq 3</math> upon diagnosis</li> </ul>

in the different selected cancer types.

- To assess 1-year OS and PFS according to the changes of NRS 2002 score and body weight during the follow-up.

### **Explorative endpoints**

- To assess 1-year OS and PFS according to the type and timing of nutritional support provided.
- To assess 1-year OS and PFS according to the body composition measured with CT scan and BIVA methods at diagnosis and during follow up.
- To assess the percentage of patients with severe toxicities oncologic and discontinuations or delays of treatment according to the NRS 2002 cut-off scores and body composition evaluated at diagnosis and during follow up.
- To explore the correlations between NRS 2002 scores, body composition parameters, type and timing of nutritional support, QoL, symptoms during follow-up.

Abbreviations: BIVA, bioelectrical impedance vector analysis; CT, computed tomography; NRS 2002, Nutritional Risk Screening 2002; OS, overall survival; PFS, progression free survival.

### ***Statistical methods and sample size***

The main characteristics of the enrolled patients at baseline will be summarized with appropriate descriptive statistics, such as absolute and relative frequencies for categorical variables, and mean or medians with corresponding precision indices (standard deviation or interquartile range) for continuous variables.

For the associations of NRS 2022 score and other nutritional factors with OS or PFS, we will use survival analysis methods, such as rate calculation, Kaplan Meier curves, and logrank test.

In addition, Cox models will be used to calculate the hazard ratio, and corresponding 95%

1  
2  
3 confidence interval, for patients at high risk of malnutrition versus low risk patients and other  
4 nutritional factors. Hazard ratios will be computed adjusting for potential confounding factors,  
5 including age, sex, tumor characteristics, stage, comorbidities, and cancer treatment. For  
6 explorative endpoints, we will use logistic regression models to calculate the (crude and  
7 adjusted) odds ratio and corresponding 95% confidence interval of severe toxicity and  
8 interruption/delay in cancer treatments, and multiple regression methods for the calculation of  
9 crude and adjusted associations.

10  
11 All analyses will be conducted using the SAS software version 9.4 (SAS Institute Inc., Cary,  
12 NC, USA).

13  
14 Considering that each center will be able to enroll between 30-300 patients/year (depending  
15 on their patients' load), we expect to enroll at least 1500 cancer patients/year. Considering an  
16 average 1-year survival rate of approximately 75% in the two sexes combined [24] and that  
17 the ratio between the number of patients not at risk and those at risk of malnutrition  
18 (NRS 2002 score  $\geq 3$ ) is approximately 2.3 [20], with this number we will be able to estimate a  
19 12-month survival hazard ratio of at least 1.36 (corresponding to a 12-month survival of  
20 0.66% in the high-risk group), with a power of 80% and an alpha error of 5%.

### 21 22 ***Patient and public involvement***

23  
24 The registry has been developed in collaboration with Italian Federation of Volunteer-based  
25 Cancer Organizations (FAVO) in order to delineate the better way to improve cancer patients'  
26 involvement into the registry.

### 27 28 ***Ethics and dissemination***

29  
30 The study will be conducted in accordance with the good clinical practice rules, the  
31 Declaration of Helsinki, and current national and European laws and regulations. The study

1  
2  
3 protocol was approved by Ethics Committee of the Fondazione IRCCS Policlinico San  
4 Matteo, Pavia, Italy (05/07/2022; prot. N. 0035571/22) and from the Ethics Committees of all  
5  
6 other participating centers. An informed consent will be obtained from each patient enrolled  
7  
8 in the study. At any time, patients will have the right to withdraw their consent without  
9  
10 modifying their current or future care. The progresses of the study will be shared with the  
11  
12 patients' general practitioners.  
13  
14  
15

16  
17 The results of the study will be presented at local, national, and international medical  
18  
19 conferences. The findings will be published in peer-reviewed medical/scientific journals and  
20  
21 made open-access on acceptance. Information may also be disseminated to cancer patients  
22  
23 and professional associations and the general population via public engagement and  
24  
25 community outreach programs.  
26  
27  
28  
29

### 30 **Discussion**

31  
32  
33 Malnutrition in oncology still represents an overlooked problem, which negatively affects  
34  
35 clinical outcomes [4,6,13,25]. An altered nutritional status brings more frequently to drug-  
36  
37 related toxicities and requires to suspend or delay anticancer therapies, resulting in reduced  
38  
39 response rates and worse prognosis [2]. Therefore, an early nutritional support since treatment  
40  
41 beginning is crucial. The target is not only to maintain or improve the nutritional status by  
42  
43 providing energy and proteins and fully satisfy nutritional requirements, but also effectively  
44  
45 impact on clinical outcomes by enhancing the adherence to anticancer treatment.  
46  
47  
48

49  
50 The global trend of research in the field of nutrition in cancer is gradually increasing [26]. To  
51  
52 date, there is evidence that an individualized nutritional support reduces the risk of mortality  
53  
54 and improves QoL in cancer patients at malnutritional risk [27]. Moreover, nutritional support  
55  
56 for oncology patients is a low-cost intervention compared to other cares [28] and it does not  
57  
58  
59  
60



1  
2  
3 require additional costs for the healthcare system [29]. However, the impact on survival still  
4  
5 requires confirmation as reliable real-world data are lacking.  
6

7 This study will allow to collect real-world clinical data on malnutrition in Italy. So, it will be  
8  
9 possible to improve the strength of evidence on the impact of malnutrition and nutritional  
10  
11 support, and to develop quality improvement programs, which help both healthcare  
12  
13 professionals to ameliorate nutritional care practices and institutions to allocate adequate  
14  
15 resources to this issue [30]. Moreover, the creation of data registry allows to study the cost-  
16  
17 effectiveness of nutritional support on a broader scale [31].  
18  
19

20  
21 The innovative aspect of this study is the implementation of the first Italian real-world register  
22  
23 for detecting malnutrition and monitoring nutritional status in cancer patients. This will allow  
24  
25 the creation of a multicentric, longitudinal cohort of oncologic patients for further research in  
26  
27 the field of nutrition in oncology. Furthermore, it will permit a better monitoring of the  
28  
29 nutritional status of cancer patients, fostering an appropriate and sustainable nutritional  
30  
31 support, with the goal to improve their care, in agreement with the most recent evidence-  
32  
33 based guidelines and recommendations [3-5,12]. The idea is to build a model for a  
34  
35 standardized digital platform to monitor the nutritional status of cancer patients. In the near  
36  
37 future, the registry could be extended to all the other oncologic centers within the national  
38  
39 territory.  
40  
41  
42  
43  
44  
45  
46

#### 47 **Acknowledgements**

48  
49 \*IRMO collaborators are the following:

50  
51 Caccialanza Riccardo, Fondazione IRCCS Policlinico San Matteo Pavia, Pavia, Italy

52  
53 Cannizzaro Renato, Centro di Riferimento Oncologico, Aviano (PN), Italy

54  
55 Casalone Valentina, Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS,

56  
57 Candiolo (TO), Italy  
58  
59  
60

1  
2  
3 Cici Rosalisa, IRCCS Saverio De Bellis, Castellana Grotte (BA), Italy  
4  
5 De Lorenzo Francesco, Italian Federation of Volunteer-based Cancer Organizations, Rome,  
6  
7 Italy  
8  
9 De Pergola Giovanni, IRCCS Saverio De Bellis, Castellana Grotte (BA), Italy  
10  
11 Di Lauro Teresa, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy  
12  
13 Fortes Cristina, IDI IRCCS - Istituto Dermopatico dell'Immacolata, Roma, Italy  
14  
15 Gori Stefania, IRCCS Sacro Cuore Don Calabria di Negrar, Valpolicella (VR), Italy  
16  
17 Elisabetta Iannelli, Italian Federation of Volunteer-based Cancer Organizations, Rome, Italy  
18  
19 Ibrahim Toni, Istituto Ortopedico Rizzoli, Bologna, Italy  
20  
21 Longhi Alessandra, Istituto Ortopedico Rizzoli, Bologna, Italy  
22  
23 Mele Maria Cristina, Policlinico Universitario Agostino Gemelli, Roma, Italy  
24  
25 Mele Roberto, IRCCS Ospedale San Raffaele, Milano, Italy  
26  
27 Montemurro Filippo, Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia -  
28  
29 IRCCS, Candiolo (TO), Italy  
30  
31 Nardi Maria Teresa, IOV Istituto Oncologico Veneto, Padova, Italy  
32  
33 Pedrazzoli Paolo, Fondazione IRCCS Policlinico San Matteo Pavia, Pavia, Italy  
34  
35 Pezzuolo Debora, AUSL IRCCS Reggio-Emilia, Italy  
36  
37 Pinto Carmine, AUSL IRCCS Reggio-Emilia, Italy  
38  
39 Pignata Sandro, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy  
40  
41 Pozzo Carmelo, Policlinico Universitario Agostino Gemelli, Roma, Italy  
42  
43 Sanchez Mete Lupe, Istituto Nazionale Tumori Regina Elena, Roma, Italy  
44  
45 Serra Patrizia, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" IRCCS, Meldola  
46  
47 (FC), Italy  
48  
49 Sukkar Samir Giuseppe, IRCCS Ospedale Policlinico San Martino, Genova, Italy  
50  
51 Tonello Marco, IOV Istituto Oncologico Veneto, Padova, Italy  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Zagonel Vittorina, IOV Istituto Oncologico Veneto, Padova, Italy  
4

### 5 **Authors' contributions**

6  
7 Conceptualization: CB, RC. Methodology: CB, RC. Software: CB. Data Curation: all authors.  
8

9  
10 Writing - Original Draft: CB, AC, EC, RC. Writing - Review & Editing: all authors.  
11

12  
13 Supervision: CB, PP, RC. Project administration: CB, PP, RC.  
14

### 15 **Funding**

16  
17 The study was supported by ACC (Bando Ricerca Corrente Reti IRCCS 2021, grant number  
18  
19 RCR-2021-23671213).  
20

### 21 **Competing interests**

22  
23 All authors declare that they have no competing interests.  
24  
25  
26  
27

## 28 **REFERENCES**

- 29  
30  
31 1. McRackan TR, Watkins JM, Herrin AE, et al. Effect of body mass index on  
32  
33 chemoradiation outcomes in head and neck cancer. *Laryngoscope* 2008;118:1180-5.  
34  
35 2. Norman K, Pichard C, Lochs H, et al. Prognostic impact of disease-related malnutrition.  
36  
37 *Clin Nutr* 2008;27:5-15.  
38  
39 3. August DA, Huhmann MB, American Society for P, et al. A.S.P.E.N. clinical guidelines:  
40  
41 nutrition support therapy during adult anticancer treatment and in hematopoietic cell  
42  
43 transplantation. *JPEN J Parenter Enteral Nutr* 2009;33:472-500.  
44  
45 4. Caccialanza R, De Lorenzo F, Gianotti L, et al. Nutritional support for cancer patients:  
46  
47 still a neglected right? *Support Care Cancer* 2017;25:3001-04.  
48  
49 5. Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer  
50  
51 patients. *Clin Nutr* 2017;36:11-48.  
52  
53 6. Hamaker ME, Oosterlaan F, van Huis LH, et al. Nutritional status and interventions for  
54  
55 patients with cancer - A systematic review. *J Geriatr Oncol* 2021;12:6-21.  
56  
57  
58  
59  
60

- 1  
2  
3 7. Brook I. Early side effects of radiation treatment for head and neck cancer. *Cancer*  
4  
5 *Radiother* 2021;25:507-13.  
6  
7
- 8 8. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on  
9  
10 definition and diagnosis [published correction appears in *Age Ageing*. 2019 Jul  
11  
12 1;48(4):601]. *Age Ageing*. 2019;48(1):16-31.  
13
- 14 9. Cereda E, Tancredi R, Klersy C, et al. Muscle weakness as an additional criterion for  
15  
16 grading sarcopenia-related prognosis in patients with cancer. *Cancer Med*.  
17  
18 2022;11(2):308-316.  
19
- 20 10. Kilgour RD, Vigano A, Trutschnigg B, et al. Handgrip strength predicts survival and is  
21  
22 associated with markers of clinical and functional outcomes in advanced cancer patients.  
23  
24 *Support Care Cancer* 2013;21:3261-70.  
25
- 26 11. Moreau J, Ordan MA, Barbe C, et al. Correlation between muscle mass and handgrip  
27  
28 strength in digestive cancer patients undergoing chemotherapy. *Cancer Med* 2019;8:3677-  
29  
30 84.  
31  
32
- 33 12. Ministero della Salute. Accordo Stato-Regioni su “Linee di indirizzo sui percorsi  
34  
35 nutrizionali nei pazienti oncologici”- Rep. atti n. 224/csr; 14/12/2017  
36  
37 [http://wwwsalutegovit/portale/documentazione/p6\\_2\\_2\\_1jsp?lingua=italiano&id=2682](http://wwwsalutegovit/portale/documentazione/p6_2_2_1jsp?lingua=italiano&id=2682)  
38  
39
- 40 13. Caccialanza R, Goldwasser F, Marschal O, et al. Unmet needs in clinical nutrition in  
41  
42 oncology: a multinational analysis of real-world evidence. *Ther Adv Med Oncol*  
43  
44 2020;12:1758835919899852.  
45  
46
- 47 14. Pedrazzoli P, Caccialanza R, Cotogni P, et al. The Advantages of Clinical Nutrition Use in  
48  
49 Oncologic Patients in Italy: Real World Insights. *Healthcare (Basel)* 2020;8  
50  
51
- 52 15. U.S. Department of Health and Human Services. Common Terminology Criteria for  
53  
54 Adverse Events (CTCAE). Versione 5.0. November 2017. Available at:  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [https://ctepcancer.gov/protocoldevelopment/electronicapplications/docs/CTCAE\\_v5\\_Quick](https://ctepcancer.gov/protocoldevelopment/electronicapplications/docs/CTCAE_v5_Quick_Reference_5x7pdf)  
4 [k\\_Reference\\_5x7pdf](https://ctepcancer.gov/protocoldevelopment/electronicapplications/docs/CTCAE_v5_Quick_Reference_5x7pdf) 2017  
5  
6  
7  
8 16. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern  
9 Cooperative Oncology Group. *Am J Clin Oncol*. 1982;5(6):649-655.  
10  
11  
12 17. Moro C, Brunelli C, Miccinesi G, et al. Edmonton symptom assessment scale: Italian  
13 validation in two palliative care settings. *Support Care Cancer* 2006;14:30-7.  
14  
15  
16 18. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of  
17 scales and preliminary tests of reliability and validity. *Med Care* 1996;34:220-33.  
18  
19  
20 19. Kondrup J, Rasmussen HH, Hamberg O, et al. Nutritional risk screening (NRS 2002): a  
21 new method based on an analysis of controlled clinical trials. *Clin Nutr* 2003;22:321-36.  
22  
23  
24 20. Bozzetti F, Mariani L, Lo Vullo S, et al. The nutritional risk in oncology: a study of 1,453  
25 cancer outpatients. *Support Care Cancer* 2012;20:1919-28.  
26  
27  
28 21. Orell-Kotikangas H, Osterlund P, Saarilahti K, et al. NRS-2002 for pre-treatment  
29 nutritional risk screening and nutritional status assessment in head and neck cancer  
30 patients. *Support Care Cancer* 2015;23:1495-502.  
31  
32  
33 22. Hersberger L, Bargetzi L, Bargetzi A, et al. Nutritional risk screening (NRS 2002) is a  
34 strong and modifiable predictor risk score for short-term and long-term clinical outcomes:  
35 secondary analysis of a prospective randomised trial. *Clin Nutr* 2020;39:2720-29.  
36  
37  
38 23. Gnagnarella P, Draga D, Misotti AM, et al. Validation of a short questionnaire to record  
39 adherence to the Mediterranean diet: An Italian experience. *Nutr Metab Cardiovasc Dis*  
40 2018;28:1140-47.  
41  
42  
43 24. ECIS. European Cancer Information System. <https://ecisjrceeuropaeu/>  
44  
45  
46 25. Baldwin C, Spiro A, Ahern R, et al. Oral nutritional interventions in malnourished  
47 patients with cancer: a systematic review and meta-analysis. *J Natl Cancer Inst*  
48 2012;104:371-85.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 26. Youn BY, Lee SY, Cho W, Bae KR, Ko SG, Cheon C. Global Trends of Nutrition in  
4  
5 Cancer Research: A Bibliometric and Visualized Analysis Study over the Past 10 Years.  
6  
7 Int J Environ Res Public Health. 2022;19(7):4165.  
8  
9  
10 27. Bargetzi L, Brack C, Herrmann J, et al. Nutritional support during the hospital stay  
11  
12 reduces mortality in patients with different types of cancers: secondary analysis of a  
13  
14 prospective randomized trial. Ann Oncol. 2021;32(8):1025-1033.  
15  
16  
17 28. Schuetz P, Sulo S, Walzer S, Krenberger S, Brunton C. Nutritional support during the  
18  
19 hospital stay is cost-effective for preventing adverse outcomes in patients with cancer.  
20  
21 Front Oncol. 2022;12:916073.  
22  
23  
24 29. Martin B, Cereda E, Caccialanza R, Pedrazzoli P, Tarricone R, Ciani O. Cost-  
25  
26 effectiveness analysis of oral nutritional supplements with nutritional counselling in head  
27  
28 and neck cancer patients undergoing radiotherapy. Cost Eff Resour Alloc. 2021;19(1):35.  
29  
30  
31 30. Arensberg MB, Richards J, Benjamin J, Kerr K, Hegazi R. Opportunities for Quality  
32  
33 Improvement Programs (QIPs) in the Nutrition Support of Patients with Cancer.  
34  
35 Healthcare (Basel). 2020;8(3):227.  
36  
37  
38 31. Vitaloni M, Caccialanza R, Ravasco P, et al. The impact of nutrition on the lives of  
39  
40 patients with digestive cancers: a position paper. Support Care Cancer. 2022;30(10):7991-  
41  
42 7996.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **FIGURE' LEGEND**  
4

5 **Figure 1.** Participating centers.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only





# BMJ Open

## MULTICENTRIC, OBSERVATIONAL, LONGITUDINAL STUDY FOR THE EVALUATION OF NUTRITIONAL MANAGEMENT IMPLICATIONS IN NEWLY DIAGNOSED ITALIAN CANCER PATIENTS: THE ITALIAN REGISTRY OF MALNUTRITION IN ONCOLOGY (IRMO)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-071858.R1
Article Type:	Protocol
Date Submitted by the Author:	22-May-2023
Complete List of Authors:	Bosetti, Cristina; Istituto di Ricerche Farmacologiche Mario Negri, Department of Oncology Casirati, Amanda; Fondazione IRCCS Policlinico San Matteo, Clinical Nutrition and Dietetics Unit Da Prat, Valentina; Fondazione IRCCS Policlinico San Matteo, Clinical Nutrition and Dietetics Unit Masi, Sara; Fondazione IRCCS Policlinico San Matteo, Clinical Nutrition and Dietetics Unit Crotti, Silvia; Fondazione IRCCS Policlinico San Matteo, Clinical Nutrition and Dietetics Unit Ferrari, Alessandra; Fondazione IRCCS Policlinico San Matteo, Medical Oncology Unit Perrone, Lorenzo; Fondazione IRCCS Policlinico San Matteo, Medical Oncology Unit Serra, Francesco; Fondazione IRCCS Policlinico San Matteo, Medical Oncology Unit Santucci, Claudia; Istituto di Ricerche Farmacologiche Mario Negri, Department of Oncology Cereda, Emanuele; Fondazione IRCCS Policlinico San Matteo, Clinical Nutrition and Dietetics Unit Iannelli, Elisabetta; Italian Federation of Volunteer-based Cancer Organizations De Lorenzo, Francesco; Italian Federation of Volunteer-based Cancer Organizations, Rome, Italy Pedrazzoli, Paolo; Fondazione IRCCS Policlinico San Matteo; University of Pavia, Internal Medicine Department Caccialanza, R; Fondazione IRCCS Policlinico San Matteo, Clinical Nutrition and Dietetics Unit IRMO Collaborators, IRMO Collaborators; Fondazione IRCCS Policlinico San Matteo
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Nutrition and metabolism
Keywords:	Quality of Life, Nutritional support < ONCOLOGY, REGISTRIES

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



SCHOLARONE™  
Manuscripts

1  
2  
3 **MULTICENTRIC, OBSERVATIONAL, LONGITUDINAL STUDY FOR THE**  
4 **EVALUATION OF NUTRITIONAL MANAGEMENT IMPLICATIONS IN NEWLY**  
5 **DIAGNOSED ITALIAN CANCER PATIENTS: THE ITALIAN REGISTRY OF**  
6 **MALNUTRITION IN ONCOLOGY (IRMO)**  
7  
8  
9  
10  
11  
12  
13

14 Cristina Bosetti<sup>1§</sup>, Amanda Casirati<sup>2</sup>, Valentina Da Prat<sup>2</sup>, Sara Masi<sup>2</sup>, Silvia Crotti<sup>2</sup>,  
15 Alessandra Ferrari<sup>3</sup>, Lorenzo Perrone<sup>3</sup>, Francesco Serra<sup>3</sup>, Claudia Santucci<sup>1</sup>,  
16 Emanuele Cereda<sup>2</sup>, Elisabetta Iannelli<sup>4</sup>, Francesco De Lorenzo<sup>4</sup>, Paolo Pedrazzoli<sup>3,5,§</sup>,  
17 Riccardo Caccialanza<sup>2§</sup>, on behalf of the IRMO collaborators\*  
18  
19  
20  
21  
22  
23  
24  
25

26 <sup>1</sup>Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan,  
27 Italy  
28

29 <sup>2</sup>Clinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy  
30

31 <sup>3</sup>Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy  
32

33 <sup>4</sup>Italian Federation of Volunteer-based Cancer Organizations, Rome, Italy  
34

35 <sup>5</sup>Internal Medicine Department, University of Pavia, Pavia, Italy  
36

37 § Co-senior authors.  
38  
39  
40  
41  
42  
43  
44

45 **Corresponding author:**

46 Dr. Riccardo Caccialanza

47 Clinical Nutrition and Dietetics Unit

48 Fondazione IRCCS Policlinico San Matteo

49 Viale Golgi 19 - 27100 Pavia, Italy

50 Tel.: +39 0382501615; fax: + 39 0382502801. E-mail: [r.caccialanza@smatteo.pv.it](mailto:r.caccialanza@smatteo.pv.it)  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

### Background

Malnutrition is a frequent problem in oncology and is associated with reduced response to cancer treatments, increased drug-related toxicity, higher rates of clinical complications, reduced quality of life (QoL), and worse prognosis. Guidelines on clinical nutrition in oncology emphasize the usefulness of early assessment of nutritional status for a prompt identification of malnutrition and the implementation of effective interventions, but no real-world clinical data are available on the adequate management of nutritional support in cancer patients in Italy.

### Methods and analysis

This is an observational, longitudinal, multicenter registry of patients with a new diagnosis of cancer or metastatic disease, candidates for active treatment. They will be identified in at least 15 Italian oncologic centers, members of the Alliance Against Cancer Working Group “Survivorship Care and Nutritional Support”. At least 1500 cancer patients are expected to be enrolled each year. Detailed clinical and nutritional data will be collected by oncologists and clinical nutritionists during the visits foreseen in the clinical practice, through an *ad hoc* developed digital platform (e-Nutracare®). The effects of malnutrition and nutritional support – at diagnosis and during follow-up – on overall survival and progression-free survival, as well as on patients’ symptoms and QoL, will be investigated.

### Ethics and dissemination

The study protocol was approved by Ethics Committee of the Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and from the Ethics Committees of all other participating centers. An informed consent will be obtained from each patient enrolled in the study. Study findings will be disseminated through peer-reviewed journals, conferences, and cancer patients or professional associations. The registry will allow a better monitoring of the nutritional status

1  
2  
3 of cancer patients, promoting adequate and sustainable nutritional support, with the ultimate  
4  
5 goal of improving the care and prognosis of these patients.  
6  
7  
8  
9

10 **Keywords:** cancer-related malnutrition, nutritional management, prospective study, quality of  
11  
12 life, real-world data, registry, survival.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

### STRENGTHS AND LIMITATIONS OF THIS STUDY

- The study will allow the implementation of the first Italian, real-world register for detecting and monitoring malnutrition in cancer patients.
- The study will make use of an *ad hoc* developed digital platform for data collection, which could be proposed and extended in the near future to other oncologic centers within the national territory.
- The study will allow a more appropriate evaluation and monitoring of cancer patients' nutritional status, promoting adequate and sustainable nutritional support, with the ultimate goal of improving the quality of care and prognosis.
- Study limitations consist in the observational design, which will not allow to compare the efficacy of personalized nutritional support interventions in specific oncologic diseases.

## INTRODUCTION

Malnutrition is a frequent problem in oncology and is associated with a reduced response to cancer treatment, an increase in treatment-related toxicity, higher occurrence of clinical symptoms and complications, impaired quality of life (QoL), and worse overall prognosis [1-6]. Different causes are linked to this condition, including factors such as cancer site and metastatic localizations, and the deregulation of systemic inflammation pathways [5]. Medical treatments and surgery could also be responsible for nutritional derangements, through the increase of basal caloric requirements and the occurrence of symptoms that negatively impact on food intake and nutrient absorption (e.g., anorexia, mucositis, dysphagia, smell alterations, taste alterations, xerostomia, vomiting, nausea, diarrhea, etc.). Taken together, these factors impair the maintenance of functional body composition [3-5,7].

Sarcopenia (i.e., the loss of skeletal muscle and strength) is the main issue which contributes to functional deterioration in cancer patients [8]. In particular, it has been observed that handgrip strength assessment is a reliable survival predictor associated with body composition variations, being also a good indicator of functional capacities in chronic diseases [9]. In oncology, low handgrip strength levels are associated with fatigue, impaired QoL, treatment-related toxicity, and higher mortality [10,11].

National and international guidelines on clinical nutrition in oncology – including those issued by the Italian Ministry of Health in 2017 [12] – underline the utility of early evaluation of nutritional status in cancer patients and of a prompt and appropriate nutritional support, whenever indicated, in order to prevent or treat malnutrition, improve patients' clinical outcomes and QoL, and increase the efficacy and tolerability of cancer treatments [3-5,12]. Only an early and adequate nutritional support can effectively prevent or treat malnutrition and support cancer patients during their entire illness trajectory.

1  
2  
3 Despite these indications, there are several critical issues related to the quality of nutritional  
4 care in oncology, and no reliable data are available on the current implementation of adequate  
5 nutritional support in cancer patients in Italy. Nowadays, only real-world data collected by  
6 administrative databases are available in the context of nutrition in oncology, but these have  
7 various inherent weaknesses, which somehow limit the possibility to interpret their evidence  
8 from a clinical point of view [13,14]. Therefore, it is of foremost importance to start  
9 collecting real-world clinical data on malnutrition in oncology, in order to strengthen the  
10 evidence and concretely improve nutritional care practices.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 Based on these premises, the study “Italian Registry of Malnutrition in Oncology (IRMO)”  
22 has been elaborated in collaboration with the oncologic centers that joined the Working Group  
23 (WG) “Survivorship Care and Nutritional Support” of Alliance Against Cancer (Alleanza  
24 Contro il Cancro, ACC). This study aims to set up a digital register of newly diagnosed cancer  
25 patients, in order to monitor their nutritional status and explore the implications of their  
26 nutritional support. This will represent the first national, real-world register for detecting and  
27 monitoring malnutrition in cancer patients and will allow the creation of a multicentric,  
28 longitudinal cohort of oncologic patients to be used for specific analyses.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

## 42 **METHODS AND ANALYSIS**

### 43 *Study design*

44  
45 This is a multicentric, longitudinal, observational registry of newly diagnosed cancer patients,  
46 candidate for active treatment. Detailed clinical and nutritional data will be collected by  
47 oncologists and clinical nutritionists during the visits foreseen in the clinical practice, through  
48 the *ad hoc* developed digital platform, e-Nutracare®. The initial duration of the study is of  
49 three years (between October 2022 and September 2025). Patients’ enrolment and follow-up  
50 will last for all the duration of the study. However, for the primary and secondary endpoints  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 of the study only patients enrolled during the first year and followed-up for another year will  
4  
5 be analyzed.  
6  
7  
8  
9

### 10 *Study subjects*

11  
12 Individuals enrolled in the study will be all consecutive newly diagnosed or treated cancer  
13  
14 patients, candidate for active treatment identified in a least 15 Italian IRCCS members of the  
15  
16 ACC WG “Survivorship Care and Nutritional Support” (**Figure 1**). They should be aged 18  
17  
18 years or more, had a new diagnosis of selected cancer sites (i.e., head and neck,  
19  
20 esophagus/stomach, colorectal, hepato-biliary, pancreatic, lung, prostate, other urogenital,  
21  
22 breast, gynecological, soft tissue sarcomas, and melanoma), or a new diagnosis of metastatic  
23  
24 disease, be eligible for active treatment, and provide informed consent to participate in the  
25  
26 registry. Individuals with impossibility to undertake the expected measurements or to  
27  
28 guarantee the attendance of the follow-up visits will be excluded.  
29  
30  
31  
32  
33  
34

### 35 *The digital platform e-Nutracare®*

36  
37 The registry data will be collected through e-Nutracare® (OPT S.r.l., Milan, Italy), a digital,  
38  
39 web-based platform specifically designed to provide the participating centers with the  
40  
41 necessary resources for data collection. The platform is accessible via an internet browser,  
42  
43 without the installation of application modules. It will enable both real-time data collection  
44  
45 during routine clinical practice visits and transmission of information to various health  
46  
47 professionals who participate in the study, thus facilitating their work, involvement, and  
48  
49 collaboration.  
50  
51  
52

53  
54 Data will be entered in single data-entry. In the electronic database, patients will be identified  
55  
56 through a unique identification code to preserve their anonymity. Separately, a list of codes  
57  
58 and corresponding identification of patients’ data will be kept. Data completeness and  
59  
60

1  
2  
3 plausibility will be remotely assessed. Once the corrections have been completed (“cleaned”  
4 database), the database will be frozen (“closed” database). Access to the application by users  
5  
6 will take place only in HTTPS, therefore the information will be always transmitted through  
7  
8 an encrypted channel. Data correction after the database closure will have to be jointly agreed  
9  
10 by the Research Manager, the Statistician and the Data Manager and appropriately  
11  
12 documented. The number of screened patients, of eligible patients and the reason for non-  
13  
14 enrollment will also be documented.  
15  
16  
17  
18  
19  
20

### 21 *Assessments*

22  
23 Medical oncologists will collect baseline data at the first patient’s visit and will carry out  
24  
25 subsequent assessments during the oncologic scheduled visits, according to treatment and  
26  
27 follow-up protocols envisaged for these patients in the clinical practice. All collected  
28  
29 variables, resumed in **Table 1**, will include:  
30  
31

- 32  
33 i) demographic, anamnestic, and clinical data (such as age, sex, cancer type, tumor stage and  
34  
35 comorbidities);  
36  
37 ii) oncologic treatments and related severe (grade  $\geq 3$ ) adverse effects or complications,  
38  
39 according to Common Terminology Criteria for Adverse Events (CTCAE v5.0) [15];  
40  
41 iii) anthropometric measurements (actual body weight, height, body mass index, weight and  
42  
43 weight trend in the previous six months);  
44  
45 iv) performance status according to the Eastern Cooperative Oncology Group (ECOG)  
46  
47 Performance Status Scale [16];  
48  
49 v) patients’ symptoms by the Edmonton Symptom Assessment Scale [17];  
50  
51 vi) QoL assessed using the Short Form 12 questionnaire [18];  
52  
53  
54  
55  
56 vii) disease outcomes (as progression or death).  
57  
58  
59  
60

**Table 1.** Collected variables.

Age, sex, cancer diagnosis, tumor stage, comorbidities.
Actual body weight, height, BMI, weight loss in the previous 6 months, NRS 2002 score.
Body composition parameters using BIVA (PhA, SPhA, FFM) and CT (SM).
Oncologic treatment, severe adverse effects (grade $\geq 3$ CTCAE).
Performance status (ECOG Scale).
Symptoms (ESAS Scale), QoL (Short Form 12).
Disease outcome (progression or death).

Abbreviations: BIVA, bioelectrical impedance vector analysis; BMI, body mass index; CT, computed tomography; CTCAE, Common Terminology Criteria for Adverse Events; ECOG, Eastern Cooperative Oncology Group; ESAS, Edmonton Symptom Assessment Scale; FFM, fat free mass; NRS 2002, Nutritional Risk Screening 2002; PhA, phase angle; QoL, quality of life; SM, skeletal muscle; SPhA, standardized phase angle.

Using anthropometric and nutritional data collected, the Nutritional Risk Screening 2002 (NRS 2002) will be calculated [5,19]. The NRS 2002 is a tool developed by the European Society of Clinical Nutrition and Metabolism, which is currently used to identify patients at risk of surgical complications and mortality and has been recently proposed as a useful tool for indicating the need of an early nutritional intervention in cancer patients [20-22].

Patients at risk of malnutrition (NRS 2002 score  $\geq 3$ ) will be referred for a nutritional examination. Clinical nutritionists will collect the following information:

i) detailed patient' nutritional requirements, nutritional support provided and adherence to the Mediterranean Diet using a validated food frequency questionnaire [23];

1  
2  
3 ii) body composition parameters obtained throughout scans of computed tomography (CT) at  
4  
5 third level of lumbar (L3) or cervical (C3) vertebra as skeletal muscle (SM) and bioelectrical  
6  
7 impedance vector analysis (BIVA), as phase angle (PhA), standardized phase angle (SPhA)  
8  
9 and fat-free mass (FFM). The measurements will be based on the availability of  
10  
11 instrumentation at the different participating centers.  
12  
13

14 Every effort will be made to ensure the accuracy of patients monitoring and to avoid patients'  
15  
16 loss at follow-up.  
17  
18

### 19 20 21 *Study endpoints* 22

23  
24 Study endpoints are described in **Table 2**. The primary endpoint will be 1-year Overall  
25  
26 Survival (OS) and Progression Free Survival (PFS) according to patients' risk of malnutrition  
27  
28 (defined as NRS 2002 score  $\geq 3$ ) upon diagnosis.  
29

30  
31 Secondary endpoints will be 1-year OS and PFS according to malnutrition risk upon diagnosis  
32  
33 in relation to cancer type, disease stage, nutritional risk changes and body weight changes  
34  
35 during follow-up (at 3, 6, 9, 12 months).  
36

37  
38 As explorative endpoints, we will investigate 1-year OS and PFS according to the type and  
39  
40 timing of nutritional support provided and body composition as well as the rate of severe  
41  
42 toxicities (grade III/IV) and discontinuation or delay of treatment according to NRS 2002  
43  
44 score and body composition. Furthermore, we will explore the correlations between NRS  
45  
46 2002 score, body composition parameters, type and timing of nutritional support, QoL,  
47  
48 symptoms, and toxicities during follow-up.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2.** Study endpoints.

<b>Primary endpoint</b>
<ul style="list-style-type: none"> <li>To assess 1-year OS and PFS according to the NRS 2002 cut-off score <math>\geq 3</math> upon diagnosis.</li> </ul>
<b>Secondary endpoints</b>
<ul style="list-style-type: none"> <li>To assess 1-year OS and PFS according to the NRS 2002 cut-off score <math>\geq 3</math> upon diagnosis of metastatic disease.</li> <li>To assess 1-year OS and PFS according to the NRS 2002 cut-off score <math>\geq 3</math> upon diagnosis in the different selected cancer types.</li> <li>To assess 1-year OS and PFS according to the changes of NRS 2002 score and body weight during the follow-up.</li> </ul>
<b>Explorative endpoints</b>
<ul style="list-style-type: none"> <li>To assess 1-year OS and PFS according to the type and timing of nutritional support provided.</li> <li>To assess 1-year OS and PFS according to the body composition measured with CT scan and BIVA methods at diagnosis and during follow up.</li> <li>To assess the percentage of patients with severe toxicities oncologic and discontinuations or delays of treatment according to the NRS 2002 cut-off scores and body composition evaluated at diagnosis and during follow up.</li> <li>To explore the correlations between NRS 2002 scores, body composition parameters, type and timing of nutritional support, QoL, symptoms during follow-up.</li> </ul>

Abbreviations: BIVA, bioelectrical impedance vector analysis; CT, computed tomography; NRS 2002, Nutritional Risk Screening 2002; OS, overall survival; PFS, progression free survival.

### ***Statistical methods and sample size***

1  
2  
3 The main characteristics of the enrolled patients at baseline will be summarized with  
4 appropriate descriptive statistics, such as absolute and relative frequencies for categorical  
5 variables, and mean or medians with corresponding precision indices (standard deviation or  
6 interquartile range) for continuous variables.  
7  
8  
9  
10

11  
12 For the associations of NRS 2022 score and other nutritional factors with OS or PFS, we will  
13 use survival analysis methods, such as rate calculation, Kaplan Meier curves, and logrank test.  
14  
15

16 In addition, Cox models will be used to calculate the hazard ratio, and corresponding 95%  
17 confidence interval, for patients at high risk of malnutrition versus low-risk patients and other  
18 nutritional factors. Hazard ratios will be computed adjusting for potential confounding factors,  
19 including age, sex, tumor characteristics, stage, comorbidities. and cancer treatment. For  
20 explorative endpoints, we will use logistic regression models to calculate the (crude and  
21 adjusted) odds ratio and corresponding 95% confidence interval of severe toxicity and  
22 interruption/delay in cancer treatments, and multiple regression methods for the calculation of  
23 crude and adjusted associations.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 All analyses will be conducted using the SAS software version 9.4 (SAS Institute Inc., Cary,  
35 NC, USA).  
36  
37  
38  
39

40 Considering that each center will be able to enroll between 30-300 patients/year (depending  
41 on their patients' load), we expect to enroll at least 1500 cancer patients/year.  
42  
43

44 Since the average 1-year survival rate for the two sexes combined is 75% [24] and about 30%  
45 of patients are at risk of malnutrition (NRS 2002 score  $\geq 3$ ) [20], we estimate a hazard ratio of  
46 12-month mortality of at least 1.36 for malnourished patients, with a power of 80% and an  
47 alpha error of 5%.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

### 58 ***Patient and public involvement***

59  
60

1  
2  
3 The registry has been developed in collaboration with Italian Federation of Volunteer-based  
4 Cancer Organizations (FAVO) in order to delineate the better way to improve cancer patients'  
5 involvement into the registry.  
6  
7  
8  
9

### 10 11 12 ***Ethics and dissemination*** 13

14 The study will be conducted in accordance with the good clinical practice rules, the  
15 Declaration of Helsinki, and current national and European laws and regulations. The study  
16 protocol was approved by Ethics Committee of the Fondazione IRCCS Policlinico San  
17 Matteo, Pavia, Italy (05/07/2022; prot. N. 0035571/22) and from the Ethics Committees of all  
18 other participating centers. An informed consent will be obtained from each patient enrolled  
19 in the study. At any time, patients will have the right to withdraw their consent without  
20 modifying their current or future care. The progresses of the study will be shared with the  
21 patients' general practitioners.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 The results of the study will be presented at local, national, and international medical  
33 conferences. The findings will be published in peer-reviewed medical/scientific journals and  
34 made open-access on acceptance. Information may also be disseminated to cancer patients  
35 and professional associations and the general population via public engagement and  
36 community outreach programs.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

### 47 **Discussion** 48

49 Malnutrition in oncology still represents an overlooked problem, which negatively affects  
50 clinical outcomes [4,6,13,25]. An altered nutritional status brings more frequently to drug-  
51 related toxicities and requires suspending or delay anticancer therapies, resulting in reduced  
52 response rates and worse prognosis [2]. Therefore, an early nutritional support since treatment  
53 beginning is crucial. The target is not only to maintain or improve the nutritional status by  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 providing energy and proteins and fully satisfy nutritional requirements, but also effectively  
4 impact on clinical outcomes by enhancing the adherence to anticancer treatment.  
5  
6

7 The global trend of research in the field of nutrition in cancer is gradually increasing [26]. To  
8 date, there is evidence that an individualized nutritional support reduces the risk of mortality  
9 and improves QoL in cancer patients at malnutritional risk [27]. Moreover, nutritional support  
10 for oncology patients is a low-cost intervention compared to other cares [28] and it does not  
11 require additional costs for the healthcare system [29]. However, the impact on survival still  
12 requires confirmation as reliable real-world data are lacking.  
13  
14

15 This study will allow to collect real-world clinical data on malnutrition in Italy. So, it will be  
16 possible to improve the strength of evidence on the impact of malnutrition and nutritional  
17 support, and to develop quality improvement programs, which help both healthcare  
18 professionals to ameliorate nutritional care practices and institutions to allocate adequate  
19 resources to this issue [30]. Moreover, the creation of data registry allows to study the cost-  
20 effectiveness of nutritional support on a broader scale [31].  
21  
22

23 The innovative aspect of this study is the implementation of the first Italian real-world register  
24 for detecting malnutrition and monitoring nutritional status in cancer patients. This will allow  
25 the creation of a multicentric, longitudinal cohort of oncologic patients for further research in  
26 the field of nutrition in oncology. Furthermore, it will permit a better monitoring of the  
27 nutritional status of cancer patients, fostering an appropriate and sustainable nutritional  
28 support, with the goal to improve their care, in agreement with the most recent evidence-  
29 based guidelines and recommendations [3-5,12]. The idea is to build a model for a  
30 standardized digital platform to monitor the nutritional status of cancer patients. In the near  
31 future, the registry could be extended to all the other oncologic centers within the national  
32 territory.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Acknowledgements

\*IRMO collaborators are the following:

Caccialanza Riccardo, Fondazione IRCCS Policlinico San Matteo Pavia, Pavia, Italy

Cannizzaro Renato, Centro di Riferimento Oncologico, Aviano (PN), Italy

Casalone Valentina, Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo (TO), Italy

Cici Rosalisa, IRCCS Saverio De Bellis, Castellana Grotte (BA), Italy

De Lorenzo Francesco, Italian Federation of Volunteer-based Cancer Organizations, Rome, Italy

De Pergola Giovanni, IRCCS Saverio De Bellis, Castellana Grotte (BA), Italy

Di Lauro Teresa, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy

Fortes Cristina, IDI IRCCS - Istituto Dermatologico dell'Immacolata, Roma, Italy

Gori Stefania, IRCCS Sacro Cuore Don Calabria di Negrar, Valpolicella (VR), Italy

Elisabetta Iannelli, Italian Federation of Volunteer-based Cancer Organizations, Rome, Italy

Ibrahim Toni, Istituto Ortopedico Rizzoli, Bologna, Italy

Longhi Alessandra, Istituto Ortopedico Rizzoli, Bologna, Italy

Mele Maria Cristina, Policlinico Universitario Agostino Gemelli, Roma, Italy

Mele Roberto, IRCCS Ospedale San Raffaele, Milano, Italy

Montemurro Filippo, Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo (TO), Italy

Nardi Maria Teresa, IOV Istituto Oncologico Veneto, Padova, Italy

Pedrazzoli Paolo, Fondazione IRCCS Policlinico San Matteo Pavia, Pavia, Italy

Pezzuolo Debora, AUSL IRCCS Reggio-Emilia, Italy

Pinto Carmine, AUSL IRCCS Reggio-Emilia, Italy

Pignata Sandro, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy

Pozzo Carmelo, Policlinico Universitario Agostino Gemelli, Roma, Italy

Sanchez Mete Lupe, Istituto Nazionale Tumori Regina Elena, Roma, Italy

Serra Patrizia, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" IRCCS, Meldola (FC), Italy

Sukkar Samir Guseppe, IRCCS Ospedale Policlinico San Martino, Genova, Italy

Tonello Marco, IOV Istituto Oncologico Veneto, Padova, Italy

Zagonel Vittorina, IOV Istituto Oncologico Veneto, Padova, Italy

### **Authors' contributions**

Conceptualization: CB, RC. Methodology: CB, RC. Software: CB. Data Curation: all authors.

Writing - Original Draft: CB, AC, EC, RC. Writing - Review & Editing: all authors.

Supervision: CB, PP, RC. Project administration: CB, PP, RC.

### **Funding**

The study was supported by ACC (Bando Ricerca Corrente Reti IRCCS 2021, grant number RCR-2021-23671213).

### **Competing interests**

All authors declare that they have no competing interests.

**REFERENCES**

1. McRackan TR, Watkins JM, Herrin AE, et al. Effect of body mass index on chemoradiation outcomes in head and neck cancer. *Laryngoscope* 2008;118:1180-5.
2. Norman K, Pichard C, Lochs H, et al. Prognostic impact of disease-related malnutrition. *Clin Nutr* 2008;27:5-15.
3. August DA, Huhmann MB, American Society for P, et al. A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. *JPEN J Parenter Enteral Nutr* 2009;33:472-500.
4. Caccialanza R, De Lorenzo F, Gianotti L, et al. Nutritional support for cancer patients: still a neglected right? *Support Care Cancer* 2017;25:3001-04.
5. Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. *Clin Nutr* 2017;36:11-48.
6. Hamaker ME, Oosterlaan F, van Huis LH, et al. Nutritional status and interventions for patients with cancer - A systematic review. *J Geriatr Oncol* 2021;12:6-21.
7. Brook I. Early side effects of radiation treatment for head and neck cancer. *Cancer Radiother* 2021;25:507-13.
8. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis [published correction appears in *Age Ageing*. 2019 Jul 1;48(4):601]. *Age Ageing*. 2019;48(1):16-31.
9. Cereda E, Tancredi R, Klersy C, et al. Muscle weakness as an additional criterion for grading sarcopenia-related prognosis in patients with cancer. *Cancer Med*. 2022;11(2):308-316.
10. Kilgour RD, Vigano A, Trutschnigg B, et al. Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. *Support Care Cancer* 2013;21:3261-70.

- 1  
2  
3 11. Moreau J, Ordan MA, Barbe C, et al. Correlation between muscle mass and handgrip  
4  
5 strength in digestive cancer patients undergoing chemotherapy. *Cancer Med* 2019;8:3677-  
6  
7 84.  
8  
9
- 10 12. Ministero della Salute. Accordo Stato-Regioni su “Linee di indirizzo sui percorsi  
11  
12 nutrizionali nei pazienti oncologici”- Rep. atti n. 224/csr; 14/12/2017  
13  
14 [http://www.salute.gov.it/portale/documentazione/p6\\_2\\_2\\_1.jsp?lingua=italiano&id=2682](http://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?lingua=italiano&id=2682)  
15  
16
- 17 13. Caccialanza R, Goldwasser F, Marschal O, et al. Unmet needs in clinical nutrition in  
18  
19 oncology: a multinational analysis of real-world evidence. *Ther Adv Med Oncol*  
20  
21 2020;12:1758835919899852.  
22  
23
- 24 14. Pedrazzoli P, Caccialanza R, Cotogni P, et al. The Advantages of Clinical Nutrition Use in  
25  
26 Oncologic Patients in Italy: Real World Insights. *Healthcare (Basel)* 2020;8  
27  
28
- 29 15. U.S. Department of Health and Human Services. Common Terminology Criteria for  
30  
31 Adverse Events (CTCAE). Versione 5.0. November 2017. Available at:  
32  
33 [https://ctep.cancer.gov/protocoldevelopment/electronicapplications/docs/CTCAE\\_v5\\_Quic](https://ctep.cancer.gov/protocoldevelopment/electronicapplications/docs/CTCAE_v5_Quick_Reference_5x7.pdf)  
34  
35 [k\\_Reference\\_5x7.pdf](https://ctep.cancer.gov/protocoldevelopment/electronicapplications/docs/CTCAE_v5_Quick_Reference_5x7.pdf) 2017  
36  
37
- 38 16. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern  
39  
40 Cooperative Oncology Group. *Am J Clin Oncol.* 1982;5(6):649-655.  
41  
42
- 43 17. Moro C, Brunelli C, Miccinesi G, et al. Edmonton symptom assessment scale: Italian  
44  
45 validation in two palliative care settings. *Support Care Cancer* 2006;14:30-7.  
46  
47
- 48 18. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of  
49  
50 scales and preliminary tests of reliability and validity. *Med Care* 1996;34:220-33.  
51  
52
- 53 19. Kondrup J, Rasmussen HH, Hamberg O, et al. Nutritional risk screening (NRS 2002): a  
54  
55 new method based on an analysis of controlled clinical trials. *Clin Nutr* 2003;22:321-36.  
56  
57
- 58 20. Bozzetti F, Mariani L, Lo Vullo S, et al. The nutritional risk in oncology: a study of 1,453  
59  
60 cancer outpatients. *Support Care Cancer* 2012;20:1919-28.

- 1  
2  
3 21. Orell-Kotikangas H, Osterlund P, Saarilahti K, et al. NRS-2002 for pre-treatment  
4 nutritional risk screening and nutritional status assessment in head and neck cancer  
5 patients. *Support Care Cancer* 2015;23:1495-502.  
6  
7
- 8  
9  
10 22. Hersberger L, Bargetzi L, Bargetzi A, et al. Nutritional risk screening (NRS 2002) is a  
11 strong and modifiable predictor risk score for short-term and long-term clinical outcomes:  
12 secondary analysis of a prospective randomised trial. *Clin Nutr* 2020;39:2720-29.  
13  
14
- 15  
16 23. Gnagnarella P, Draga D, Misotti AM, et al. Validation of a short questionnaire to record  
17 adherence to the Mediterranean diet: An Italian experience. *Nutr Metab Cardiovasc Dis*  
18 2018;28:1140-47.  
19  
20
- 21  
22 24. ECIS. European Cancer Information System. <https://ecisjrceeuropaeu/>  
23  
24
- 25  
26 25. Baldwin C, Spiro A, Ahern R, et al. Oral nutritional interventions in malnourished  
27 patients with cancer: a systematic review and meta-analysis. *J Natl Cancer Inst*  
28 2012;104:371-85.  
29  
30
- 31  
32 26. Youn BY, Lee SY, Cho W, Bae KR, Ko SG, Cheon C. Global Trends of Nutrition in  
33 Cancer Research: A Bibliometric and Visualized Analysis Study over the Past 10 Years.  
34 *Int J Environ Res Public Health*. 2022;19(7):4165.  
35  
36
- 37  
38 27. Bargetzi L, Brack C, Herrmann J, et al. Nutritional support during the hospital stay  
39 reduces mortality in patients with different types of cancers: secondary analysis of a  
40 prospective randomized trial. *Ann Oncol*. 2021;32(8):1025-1033.  
41  
42
- 43  
44 28. Schuetz P, Sulo S, Walzer S, Krenberger S, Brunton C. Nutritional support during the  
45 hospital stay is cost-effective for preventing adverse outcomes in patients with cancer.  
46 *Front Oncol*. 2022;12:916073.  
47  
48
- 49  
50 29. Martin B, Cereda E, Caccialanza R, Pedrazzoli P, Tarricone R, Ciani O. Cost-  
51 effectiveness analysis of oral nutritional supplements with nutritional counselling in head  
52 and neck cancer patients undergoing radiotherapy. *Cost Eff Resour Alloc*. 2021;19(1):35.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 30. Arensberg MB, Richards J, Benjamin J, Kerr K, Hegazi R. Opportunities for Quality  
4 Improvement Programs (QIPs) in the Nutrition Support of Patients with Cancer.  
5 Healthcare (Basel). 2020;8(3):227.  
6  
7  
8  
9  
10 31. Vitaloni M, Caccialanza R, Ravasco P, et al. The impact of nutrition on the lives of  
11 patients with digestive cancers: a position paper. Support Care Cancer. 2022;30(10):7991-  
12 7996.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 **FIGURE' LEGEND**  
4

5 **Figure 1.** Participating centers.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40